NL
VRTX icon

NKCFO LLC’s Vertex Pharmaceuticals VRTX Stock Holding History

NKCFO LLC’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,243
Closed -$3.83M – 134
2024
Q3 		$3.83M Hold
8,243
– – 1.83% 15
2024
Q2 		$3.86M Sell
8,243
-147
-2% -$63.8K 2.11% 12
2024
Q1 		$3.51M Sell
8,390
-35
-0.4% -$14.8K 2.09% 13
2023
Q4 		$3.43M Hold
8,425
– – 1.86% 15
2023
Q3 		$2.93M Hold
8,425
– – 1.63% 16
2023
Q2 		$2.96M Sell
8,425
-160
-2% -$53.9K 1.37% 22
2023
Q1 		$2.71M Hold
8,585
– – 1.3% 22
2022
Q4 		$2.48M Buy
8,585
+70
+0.8% +$21.3K 1.16% 24
2022
Q3 		$2.46M Hold
8,515
– – 1.14% 28
2022
Q2 		$2.4M Buy
8,515
+40
+0.5% +$10.7K 0.84% 31
2022
Q1 		$2.21M Buy
8,475
+8,025
+1,783% +$1.9M 0.69% 33
2021
Q4 		$99K Buy
+450
New +$87.5K 0.03% 87

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

NKCFO LLC's VRTX Position: Q4 2024 in Review

NKCFO LLC sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 8,243 shares — an estimated $3.83M sold.

NKCFO LLC first reported a position in VRTX in Q4 2021 and held it in 12 quarters. The position peaked at $3.86M in Q2 2024. 1,557 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • NKCFO LLC reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • NKCFO LLC sold 8,243 Vertex Pharmaceuticals shares in Q4 2024, an estimated $3.83M.
  • NKCFO LLC first reported a position in Vertex Pharmaceuticals in Q4 2021 and held it in 12 quarters.
  • NKCFO LLC's Vertex Pharmaceuticals position peaked at $3.86M in Q2 2024.
  • 1,557 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on NKCFO LLC's 13F filing for Q4 2024, filed 30 Jan 2025.